Search ARM

Mahzi is focused on treating under-served rare genetic neurodevelopmental disorders. Based on the Greek word for ‘Together’, Mahzi will unite patient and family groups, academic researchers, other industry members, and its internal team of experts to develop therapies for patients with these serious diseases. Mahzi has raised approximately $56 million from top venture capital firms and expects to initiate clinical trials for its most advanced AAV9 program in 2024.

Contact Mahzi Therapeutics
Visit Website